title: Introducing Hyperthermic Intraperitoneal Chemotherapy into Gynecological Oncology Practice - Feasibility and Safety Considerations: Single-Center Experience.
abstract: BACKGROUND
  Within the surgical oncology community interest is increasingly focusing on combining surgical cytoreduction and regional chemotherapeutic drug delivery to manage solid abdominal tumors. In particular, the role of hyperthermic intraperitoneal chemotherapy (HIPEC) is evolving for treating epithelial ovarian carcinomas (EOCs), as EOCs remain confined to the peritoneal cavity for most of their natural history. Currently there is no evidence from prospective trials to confirm an overall survival benefit associated with HIPEC. In addition, there are no generally accepted regimens, which results in heterogeneous clinical procedures.
  
  
  METHODS
  We have initiated a HIPEC program at our institution and completed a phase I study of HIPEC with cisplatin in patients with platinum-sensitive recurrent EOC. The data have been published and prove the feasibility of this approach. In the process of introducing HIPEC, several safety measures had to be taken into consideration.
  
  
  RESULTS
  We present the implications and requirements of introducing HIPEC in clinical practice and discuss our proposed procedure referring to the recent literature.
  
  
  CONCLUSIONS
  HIPEC is feasible and can be performed safely in daily gynecological oncology routine provided that certain considerations and precautions are taken into account during its introduction to guarantee a proper and safe operating sequence.
authors.affiliation: Department of Obstetrics and Gynecology, Center for Integrated Oncology, University Hospital Bonn, Bonn, Germany.
authors.forename: Alina
authors.initials: A
authors.lastname: Abramian
authors.forename: Oliver
authors.initials: O
authors.lastname: Zivanovic
authors.forename: Walther
authors.initials: W
authors.lastname: Kuhn
authors.forename: Stefan
authors.initials: S
authors.lastname: Weber
authors.forename: Nico
authors.initials: N
authors.lastname: Schaefer
authors.forename: Mignon-Denise
authors.initials: MD
authors.lastname: Keyver-Paik
authors.forename: Nicholas
authors.initials: N
authors.lastname: Kiefer
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D000077216:Carcinoma, Ovarian Epithelial; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000009:adverse effects / Q000379:methods*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D003131:Combined Modality Therapy / Q000009:adverse effects / Q000379:methods; D003452:Cryosurgery / Q000009:adverse effects / Q000379:methods*; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D009375:Neoplasms, Glandular and Epithelial / Q000473:pathology / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy*; D010865:Pilot Projects; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin